LY-334370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.

[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.

[4] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.